Preventing the progression of a blood condition linked to cancer
Official title: Prevent IgM MGUS Progression by Targeting the Driver Mutation
Funded at Baylor College of Medicine · NIH-10910170 · Data updated 2026-11-12
This study is looking at patients with a condition called MGUS, which can lead to serious blood cancers, and it aims to find new treatments by focusing on a specific mutation that may help prevent the disease from getting worse.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $473,744 |
| NIH project number | 5U54CA272691-02 |
| Project ID | NIH-10910170 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with IgM MGUS who are at risk for progression to more severe hematological malignancies.
✕Less likely to help
Patients who do not have IgM MGUS or those with advanced stages of blood cancers may not benefit from this research.
What this research studies
This research focuses on patients with IgM monoclonal gammopathy of undetermined significance (MGUS), who are at risk for developing serious blood cancers. The study aims to target a specific mutation (MYD88 L265P) that is commonly associated with these conditions using advanced artificial intelligence to identify potential therapeutic compounds. By understanding how this mutation drives cancer progression, the research seeks to develop strategies to prevent the transition from MGUS to more severe diseases like Waldenstrom macroglobulinemia and non-Hodgkin lymphoma. Patients may benefit from new treatment options that could halt or slow disease progression.
Why it matters
Potential benefit: If successful, this research could provide new preventive therapies for patients at risk of developing serious blood cancers.
How similar studies have gone: Previous research has shown promise in targeting specific mutations in cancer prevention, making this approach both innovative and grounded in prior success.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Yu, Xinfang — Baylor College of Medicine
- Study coordinator: Yu, Xinfang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.